Advances in targeted therapies and emerging strategies for blood cancer treatment

Abstract

Blood cancers, including leukemia, lymphoma, and multiple myeloma, originate within the bone marrow, where the intricate microenvironment presents considerable challenges for conventional therapies such as chemotherapy, immunotherapy, radiotherapy, and hematopoietic stem cell transplantation. These approaches often suffer from poor specificity, low bioavailability, and systemic toxicity, resulting in suboptimal treatment outcomes. In response, significant advances in targeted drug delivery systems, including liposomes, pegylated formulations, and polymeric nanoparticles have been developed to enhance drug stability, prolong circulation time, and improve tumor accumulation while reducing off-target effects. This review provides a comprehensive overview of recent innovations in ligand-directed drug delivery systems for blood cancers. Emphasis is placed on systems functionalized with antibodies, peptides, aptamers, and proteins designed to overcome the barriers of the bone marrow niche and enable selective delivery to malignant cells. Notably, leukemia has emerged as a key model for evaluating these technologies, with promising preclinical and clinical results. However, despite technological progress, critical translational challenges remain. These include biological heterogeneity, variability in target receptor expression, immunogenicity of nanoparticles, and the complexity of scaling multifunctional delivery systems under clinical conditions. Furthermore, current in vitro and in vivo models fail to accurately recapitulate the bone marrow's dynamic physiology, underscoring the need for improved predictive systems. Future perspectives suggest the integration of personalized nanomedicine approaches that adapt to patient-specific genetic profiles and disease states. Additionally, artificial intelligence (AI) and big data analytics are expected to revolutionize delivery optimization, biomarker discovery, and therapy customization. Ultimately, interdisciplinary collaboration is required to bridge the gap between bench and bedside. By addressing current limitations and embracing innovation, the field moves closer to realizing safe, precise, and effective therapies for patients with hematologic malignancies.

Graphical abstract: Advances in targeted therapies and emerging strategies for blood cancer treatment

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Review Article
Submitted
31 Mar 2025
Accepted
18 Jun 2025
First published
01 Jul 2025
This article is Open Access
Creative Commons BY-NC license

RSC Pharm., 2025, Advance Article

Advances in targeted therapies and emerging strategies for blood cancer treatment

S. A. Adeyemi, L. M. Ngema and Y. E. Choonara, RSC Pharm., 2025, Advance Article , DOI: 10.1039/D5PM00090D

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements